Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1269533 | 1.00 | BACE1 (0.49) | BACE1CYP26A1CYP19A1MCHR1ITGB3 | |
| Hydrochloric Acid SCHEMBL4622190 | 0.99 | BACE1 (0.49) | BACE1CYP26A1CYP19A1MCHR1ITGB3 | |
| SCHEMBL29487571 | 0.90 | BACE1 (0.56) | BACE1CYP26A1CYP19A1MCHR1ITGB3 | |
| SCHEMBL1269195 | 0.90 | BACE1 (0.56) | BACE1CYP26A1CYP19A1MCHR1ITGB3 | |
| Hydrochloric Acid SCHEMBL4622508 | 0.89 | BACE1 (0.56) | BACE1CYP26A1CYP19A1MCHR1ITGB3 | |
| SCHEMBL1269207 | 0.88 | BACE1 (0.52) | BACE1CYP26A1CYP19A1MCHR1ITGB3 | |
| Hydrochloric Acid SCHEMBL4622514 | 0.87 | BACE1 (0.52) | BACE1CYP26A1CYP19A1MCHR1ITGB3 | |
| SCHEMBL29487567 | 0.84 | BACE1 (0.56) | BACE1CYP26A1CYP19A1MCHR1ITGB3 | |
| SCHEMBL1269557 | 0.84 | BACE1 (0.67) | BACE1CYP26A1MCHR1ITGB3ITGA2B | |
| SCHEMBL1268167 | 0.84 | BACE1 (0.56) | BACE1CYP26A1CYP19A1MCHR1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122071471-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-22 | — | — | CN | disclosed |
| US-12630509-B2 | Heterocyclic NMDA antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-19 | — | — | US | disclosed |
| CN-122010945-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-12 | — | — | CN | disclosed |
| CN-122010946-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-12 | — | — | CN | disclosed |
| EP-4680611-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2026-01-21 | — | — | EP | disclosed |
| WO-2025229495-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-11-06 | — | — | WO | disclosed |
| WO-2025229494-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-11-06 | — | — | WO | disclosed |
| EP-4626546-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2025-10-08 | — | — | EP | disclosed |
| EP-4612145-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2025-09-10 | — | — | EP | disclosed |
| EP-4508027-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2025-02-19 | — | — | EP | disclosed |
| US-20230134307-A1 | HETEROCYCLIC NMDA ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-04 | — | — | US | disclosed |
| US-20230002318-A1 | HETEROCYCLIC NMDA ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-05 | — | — | US | disclosed |
| EP-4058430-A1 | HETEROCYCLIC NMDA ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2022-09-21 | — | — | EP | disclosed |
| WO-2022190060-A1 | AN OREXIN 2 RECEPTOR AGONIST FOR THE TREATMENT OF AN OREXIN-MEDIATED DISEASE OR DISORDER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-15 | — | — | WO | disclosed |
| CN-115003670-A | Heterocyclic compounds | 武田药品工业株式会社 | 2022-09-02 | — | — | CN | disclosed |
| CN-111051295-B | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2022-09-02 | — | — | CN | disclosed |
| CN-114980892-A | TAK-925 for the treatment of narcolepsy | 武田药品工业株式会社 | 2022-08-30 | — | — | CN | disclosed |
| EP-4034257-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2022-08-03 | — | — | EP | disclosed |
| CN-114555083-A | Use of orexin 2 receptor agonists for the treatment of excessive sleepiness | 武田药品工业株式会社 | 2022-05-27 | — | — | CN | disclosed |
| CN-114181136-A | Substituted piperidine compounds and uses thereof | 武田药品工业株式会社 | 2022-03-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630509-B2 | Heterocyclic NMDA antagonists | GRIN1, GRIN3A, GRIN2B | BACE1 484/4885CYP26A1 2616/4885CYP19A1 3014/4885 |
| US-20230002318-A1 | HETEROCYCLIC NMDA ANTAGONISTS | GRIN1, GRIN2B, GRIN2A | BACE1 382/4885CYP26A1 3680/4885CYP19A1 3487/4885 |
| US-20230134307-A1 | HETEROCYCLIC NMDA ANTAGONISTS | GRIN1, GRIN2B, GRIN2A | BACE1 382/4885CYP26A1 3680/4885CYP19A1 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.